5 hours Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue EstimatesZacks
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 8.47% and 3.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X